[Source]
Cambrex has announced changes to its management team and Board of Directors. The following appointments and new positions are effective immediately.
- Robert Green has been named Executive Vice President and Chief Financial Officer, succeeding Gregory Sargen, who will depart the company on January 31. Green joins from General Electric Corporation, where he began his career in 1990 and was most recently CFO of GE Power, a global business unit with $35 billion in revenue operating in 180 countries. In his tenure at GE, Robert served as CFO for eight global business units, including as CFO of GE Healthcare Bio-Sciences, a leading medical diagnostic and life sciences products company.
- Shawn Cavanagh has been promoted to President and Chief Operating Officer, and will join the Company’s Board of Directors. Shawn has served as EVP and Chief Operating Officer of Cambrex since 2011, having originally joined in 1999, and has been instrumental to the company’s long-term growth and strategic development.
- Stephan Haitz has been promoted to President, CDMO Sales & Marketing. Haitz joined Cambrex in 2014 and has served as Vice President, Sales & Business Development. Stephan previously held various sales and business development roles at Lonza and Solvias AG.
The Company’s Board of Directors will now be comprised of Chairman Wayne Hewett, CEO Steven Klosk, President Shawn Cavanagh, Claes Glassell, who will be rejoining the Board, Permira Partners John Coyle and Henry Minello and Permira Principal Laura O’Donnell.
“I’m proud of the depth and experience of our talented team, which is reflected in the quality of individuals transitioning to these leadership roles,” Steven Klosk, CEO of Cambrex, said. “We are well-positioned for continued growth in the market given our best-in-class assets, broad product capabilities and customer reputation. I’m thrilled to be working with this group of individuals and look forward to the strong future ahead.”
“I am incredibly honored to serve as Chairman during this inflection point in Cambrex’s history,” Wayne Hewett, Chairman of the Board, said. “The management team and Board have a remarkable combination of healthcare leadership experience and operational expertise and, following the Permira funds’ investment, are well-positioned to support Cambrex’s growth and expanded product offering to better serve leading pharmaceutical companies around the world.”